Vertex Pharmaceuticals (VRTX) Notes Payables (2016 - 2017)
Vertex Pharmaceuticals (VRTX) recorded quarterly Notes Payables of $232.4 million in Q4 2017, up 22.14% quarter-over-quarter from $190.3 million in Q3 2017, and up 216.55% on a YoY basis from $73.4 million in Q4 2016.
Vertex Pharmaceuticals (VRTX) Notes Payables (2016 - 2017) Analysis & Trends
Vertex Pharmaceuticals' Notes Payables history runs 2 years deep, the most recent figure standing at $232.4 million for Q4 2017.
- In Q4 2017, Notes Payables rose 216.55% year-over-year to $232.4 million; the TTM figure through Dec 2017 stood at $232.4 million (up 216.55% YoY), while the FY2017 annual figure was $232.4 million, up 216.55% from the prior year.
- Notes Payables was $232.4 million for Q4 2017 at Vertex Pharmaceuticals, up from $190.3 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $232.4 million in Q4 2017 to a low of $73.4 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 232.40 Mn |
| Sep 30, 2017 | 190.27 Mn |
| Jun 30, 2017 | 147.69 Mn |
| Mar 31, 2017 | 104.77 Mn |
| Dec 31, 2016 | 73.42 Mn |